Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc. has reported its recent financial performance, with a market capitalization of $286.42 million and a price-to-earnings ratio of -6.42, as the company continues to focus on developing treatments for central nervous system d…

Vanda Pharmaceuticals Inc. has reported a strong first quarter in 2025, driven by commercial success with Fanapt and promising pipeline developments, positioning the company for continued growth and future success.